

CITATION REPORT

List of articles citing

Crizanlizumab 5.0 Mg/Kg Exhibits a Favorable Safety Profile in Patients with Sickle Cell Disease: Pooled Data from Two Phase II Studies

DOI: 10.1182/blood-2019-123965
Blood, 2019, 134, 991-991.

Source: <https://exaly.com/paper-pdf/86456386/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|---|---|-----|-----------|
| 5 | P-selectin blockade in COVID-19-related ARDS. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020 , 318, L1237-L1238 | 5.8 | 24 |
| 4 | Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease. <i>Pharmacotherapy</i> , 2020 , 40, 535-543 | 5.8 | 8 |
| 3 | A critical evaluation of crizanlizumab for the treatment of sickle cell disease.. <i>Expert Review of Hematology</i> , 2021 , 1-9 | 2.8 | 0 |
| 2 | Hydroxyurea (hydroxycarbamide) for sickle cell disease. 2022 , 2022, | | 3 |
| 1 | Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine. 2022 , 10, 123 | | 0 |